Risiko für venöse Thromboembolien bei Patienten mit Krebs, die den Angiogenese-Hemmer Bevacizumab erhalten

Key Points

Key points are not available for this paper at this time.

Abstract

Die Anwendung von Bevacizumab war signifikant mit einem erhöhten Risiko für die Entwicklung von venösen Thromboembolien bei Krebspatienten verbunden, die dieses Medikament erhielten.

Bookmark

Cite This Study

Nalluri et al. (Tue,) haben diese Frage untersucht.

synapsesocial.com/papers/69daa4e785037e71b2684599 https://doi.org/https://doi.org/10.1001/jama.2008.656

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis2007 · 630 citations
2Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor1998 · 143 citations
3Selecting and Appraising Studies for a Systematic Review1997 · 284 citations
4Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer2006 · 23 citations
5Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer2004 · 350 citations